CASE REPORT

The dilemma in a case of immune thrombocytopenia in a patient with human immunodeficiency virus on antituberculosis treatment for miliary pulmonary tuberculosis

Nata Pratama Hardjo Lugito1,*, Jane Olivia Lorens2, Jessica Kwenandar2 and Andree Kurniawan1

1Internal Medicine Department, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman, Lippo Karawaci, Tangerang, Banten 15811, Indonesia, 2Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman, Lippo Karawaci, Tangerang, Banten 15811, Indonesia

*Correspondence address. Internal Medicine Department, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman, Lippo Karawaci, Tangerang, Banten, Indonesia 15811. Tel: +622154210130; Fax: +622154210133; E-mail: nata.lugito@uph.edu

Abstract

The multifactorial mechanisms of immune thrombocytopenia (ITP) in patients with human immunodeficiency virus (HIV) and tuberculosis (TB) could be caused by HIV, TB or anti-TB drugs. No patients with HIV and opportunistic infection of miliary pulmonary TB who developed thrombocytopenia after treatment with anti-TB drugs have been reported. A 47-year-old woman with HIV/acquired immunodeficiency syndrome and miliary TB with normal platelet count (229,000/μL) started anti-TB drugs (rifampicin, isoniazid, pyrazinamide and ethambutol). After 10 days of treatment, her platelet count was low (17,000/μL). As rifampicin and isoniazid were stopped and intravenous methylprednisolone was given, her platelet count began to increase. After more than a month, her platelet count was normal (192,000/μL) and she started antiretrovirals. This improved platelet count after high-dose methylprednisolone is suggestive of ITP; however, the dilemma is whether it was rifampicin alone that caused ITP or did HIV and disseminated TB infection also play a role?

INTRODUCTION

Thrombocytopenia in patients with human immunodeficiency virus (HIV) is associated with increased morbidity and mortality in addition to HIV infection or opportunistic infections, such as tuberculosis (TB) [1]. Thrombocytopenia in a patient with TB might be caused by various mechanisms, such as immune thrombocytopenia (ITP) or anti-TB drug-induced thrombocytopenia, among other things [2]. To our knowledge, no patients with HIV and opportunistic miliary pulmonary TB infection who developed ITP after treatment with anti-TB drugs have been reported.
anti-TB therapy (rifampicin 450 mg/day, isoniazid 300 mg/day, pyrazinamide 1000 mg/day and ethambutol 1000 mg/day) and trimethoprim/sulfamethoxazole 960 mg/day. Her initial hematological test showed a normal platelet count. Her vital signs were within the normal range when she was admitted. A physical examination showed icteric sclerae, no hepatomegaly or splenomegaly, generalized multiple erythematous papules and excoriation and multiple purpuric lesions on her upper extremities. Hematology results were similar to the initial result but with a low platelet count (17 000/μL). Peripheral blood smear morphology showed hypochromic microcytic erythrocytes, with polychromatina and target cells, but no nucleated erythrocytes. Her leucocyte count was within the normal range, but the platelet count was low with no giant thrombocytes. She also had increased transaminases and bilirubin levels.

Her abdominal ultrasonography was normal. Viral hepatitis markers (surface antigen of the hepatitis B virus and antibodies to hepatitis C virus) and dengue serology were negative. Rifampicin, isoniazid and pyrazinamide were stopped, ethambutol was continued and streptomycin was started (1000 mg/day). She was also given oral methylprednisolone 16 mg twice/day for the skin lesions. On the eighth day, intravenous methylprednisolone 125 mg/day was given for 3 days and tapered down to 62.5 mg/day for the next 3 days. On the 13th day, her platelet count was 84 000/μL and she was discharged with oral methylprednisolone 16 mg thrice/day. She returned to the outpatient clinic on the 22nd day, and the platelet count curve is shown in Fig. 1.

DISCUSSION

Thrombocytopenia is defined as a platelet count below 150 000/μL, while ITP is defined as a platelet count below 100 000/μL caused by the immune destruction of platelets. Secondary ITP is associated with infectious and noninfectious diseases, such as autoimmune disease, TB, HIV, hepatitis C virus, Helicobacter pylori or immune dysregulation syndromes [3].

Around 40% of patients with HIV develop thrombocytopenia during the disease course [5]. Thrombocytopenia in patients with HIV could be caused primarily by HIV or secondarily by opportunistic infections, such as TB [2]. In primary thrombocytopenia, the causes differ in different stages of HIV, where autoimmune destruction predominates in early stages, while defective thrombopoiesis predominates in the late stages [1]. In secondary thrombocytopenia, opportunistic infections are important causes and TB is the most common [2,4,5].

Thrombocytopenia in a patient with TB was caused by various mechanisms, including immune-mediated platelet destruction and anti-TB drug-induced thrombocytopenia, among other mechanisms. Thrombocytopenia is most commonly seen in pulmonary and disseminated TB [6] and responds well to anti-TB drugs [2]. Isolated thrombocytopenia in patients with TB is rare and hypothesized to be a secondary ITP. One review identified only 50 cases of secondary ITP associated with TB between 1964 and 2016 [7]. Anti-TB drug-induced thrombocytopenia could be caused by isoniazid, rifampicin or both, where autoimmune- mediated rifampicin is the most common [8,9]. The exact mechanism of isoniazid-induced thrombocytopenia is not known [9], and thrombocytopenia caused by isoniazid and rifampicin was reported only once previously [8].

A systematic review defined standard criteria to determine that a drug induces thrombocytopenia [10], but they were not applicable in this case because there were multiple drugs prior to the onset of thrombocytopenia. For example, two drugs could cause thrombocytopenia: isoniazid and rifampicin. Many etiologies of thrombocytopenia were present in this patient, including HIV and TB infections. Isoniazid and rifampicin could not be reintroduced because of the suspicion of drug-induced liver injury. Only one criterion could be fulfilled in this patient, which was that the suspected drugs preceded her thrombocytopenia, and her recovery was complete and sustained after both drugs were withdrawn.

The patient had no personal or family history of thrombocytopenia. Her hepatitis C serology was negative, although H. pylori was not examined. Her peripheral blood smear was suggestive of ITP. Antiplatelet antibody testing was not recommended in this case because of high interlaboratory variability and poor sensitivity [6]. HIV and disseminated TB could cause ITP in this patient, but her platelet count was normal when she was diagnosed with HIV and TB and antiretrovirals were not

---

**Table 1: Laboratory results of the patient**

| Laboratory          | Reference values | –10  | 1  | 3  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 22 | 37 | 51 |
|---------------------|------------------|------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Hemoglobin (g/dl)   | 12.0–15.0        | 9.8  | 9.5| 9.2| 9.3| 8.3| 8.7| 8.1| 8.4| 7.9| 8.0| 8.6| 7.9 | 8.7|10.6 |11.3|
| Hematocrit (%)      | 36.0–47.0        | 29.0| 27.8| 28.4| 29.1|26.6|26.6|24.9|24.6|24.1|23.3|25.0|24.1|27.6|33.3|33.0|
| Erythrocyte (x 10^5/μl) | 4.20–5.90       | 3.58| 3.43| 3.38| 3.40|3.01|3.16|2.95|2.96|2.87|2.78|2.95|2.77|2.84|3.18|3.47|
| Leucocyte (/μl)     | 4.00–10.00       | 4.13| 4.23| 2.95| 3.25|2.27|2.59|2.58|1.88|2.06|2.26|3.23|2.90|5.72|5.28|3.65|
| Platelet (x 10^9/μl)| 150–350          | 229 | 17 | 8  | 7  | 13 | 4  | 6  | 7  | 17 | 18 | 42 | 84 | 99 |192 |201|
| Total bilirubin (mg/dl) | 0.30–1.20     | 9.53| 7.24| 6.38| 3.28| 6.12| 2.83| 0.84| 0.12| 0.26| 0.45| 0.84| 0.12| 0.26| 0.45|
| Direct bilirubin (mg/dl) | 0.00–0.30     | 8.69| 7.12| 6.12| 2.83| 0.84| 0.12| 0.26| 0.45| 0.84| 0.12| 0.26| 0.45| 0.84| 0.12| 0.26|
| Indirect bilirubin (mg/dl) | 0.30–0.90    | 117 | 67  | 82  | 69 | 141| 90 | 62 | 81|
| AST (U/l)           | 0–35            | 117 | 67  | 82  | 69 | 141| 90 | 62 | 81|
| ALT (U/l)           | 0–35            | 117 | 67  | 82  | 69 | 141| 90 | 62 | 81|

AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase
given. The patient was on anti-TB treatment, which could have caused thrombocytopenia. Her platelet count began to decrease as the anti-TB treatment started. Her thrombocytopenia was suggestive of secondary ITP due to rifampicin. On the first day of admission, methylprednisolone was already given and both rifampicin and isoniazid discontinued. Although rifampicin was the most probable cause of ITP, HIV and TB could not be excluded convincingly. Although steroids have no benefit in the management of drug-induced thrombocytopenia, steroids could be given in severe thrombocytopenia where it is difficult to determine a cause of thrombocytopenia where multiple causes are present, such as in this case [8].

CONCLUSION
We reported a case of secondary ITP in a patient with HIV treated with isoniazid and rifampicin for miliary pulmonary TB. There was a dilemma in this case because rifampicin alone could have been the prime suspect for ITP, but HIV and disseminated TB infection were also not innocent bystanders.

ACKNOWLEDGEMENTS
None.

CONFLICT OF INTEREST STATEMENT
None declared.

FUNDING
All authors declare no financial disclosure or competing interests and approved this submission.

ETHICAL APPROVAL
No ethical approval was required.

CONSENT
Written informed consent was obtained from the patient for publication of this report.

GUARANTOR
N.P.H.L. is the guarantor of this article.

REFERENCES
1. Chandra N, Bhavnadhar P, Satyanarayana Raju Y, Shanthweer U. HIV associated thrombocytopenia. J Clin Sci Res 2012;1:187–91.
2. Bairagya TD, Das SK, Jana PK, Bhattacharya S. Immune thrombocytopenic purpura associated with pulmonary tuberculosis. J Global Infect Dis 2012;4:175–7.
3. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood 2017;129:2829–35.
4. Babina S, Kumar TJ, Roy M, Konjenbam R. Thrombocytopenia in HIV/AIDS. IOSR J Dent Med Sci 2015;14:9–11.
5. Sandhya AS, Prajapat B. Thrombocytopenia in HIV patients coinfected with tuberculosis. J Family Med Prim Care 2017;6:859–61.
6. Krishna MR, Gottam US, Mahendra N. Disseminated tuberculosis with severe immune thrombocytopenia. Respir Med Case Rep 2019;27:100812.
7. Weber SF, B’elard S, Rai S, Reddy R, Belurkar S, Saravu K. Immune thrombocytopenia secondary to tuberculosis: a case and review of literature. Int. J Tuberc Lung Dis 2017;21:466–70.
8. Yakar F, Yildiz N, Yakar A, Kılıçaslan Z. Isoniazid- and rifampicin-induced thrombocytopenia. Multidiscip Respir Med 2013;8:13.
9. Dosi R, Chandelkar A, Jain A, Motiwale S, Joshi P, Jain P. Rifampicin-induced thrombocytopenia: a rare complication. J Assoc Chest Physicians 2018;7:38–40.
10. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S et al. Drug induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886–90.